Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Switch to English

10473	Sociétés
220564	Mots-clés
149886	Articles
116642	Communiqués

Accueil
Sociétés
Protagonist Therapeutics, Inc.

COMMUNIQUÉ DE PRESSE

publié le 15/09/2025 à 16:45, il y a 8 mois 15 jours

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Protagonist Therapeutics to present Phase 2b ANTHEM-UC study data on targeted oral peptide icotrokinra at UEGW Week 2025 in Berlin. Company focuses on advanced therapies in ulcerative colitis

Ulcerative Colitis Protagonist Therapeutics Icotrokinra Phase 2b ANTHEM-UC Study UEGW Week 2025
BRÈVE

publiée le 11/09/2025 à 14:05, il y a 8 mois 19 jours

Un acteur majeur sollicite l'approbation de l'EMA pour l'icotrokinra dans le traitement du psoriasis

Essais Cliniques Icotrokinra Psoriasis En Plaques Efficacité Du Traitement Demande D'admission À L'EMA
BRÈVE

publiée le 11/09/2025 à 14:05, il y a 8 mois 19 jours

Protagonist Seeks EMA Approval for Icotrokinra in Psoriasis

Clinical Trials Plaque Psoriasis Icotrokinra Treatment Efficacy EMA Application
COMMUNIQUÉ DE PRESSE

publié le 11/09/2025 à 14:00, il y a 8 mois 19 jours

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Protagonist Therapeutics submits application to EMA for first approval of icotrokinra, an investigational targeted oral peptide blocking IL-23 receptor in plaque psoriasis treatment

Protagonist Therapeutics Plaque Psoriasis Treatment IL-23 Receptor Icoktrokinra EMA Submission
BRÈVE

publiée le 26/08/2025 à 22:10, il y a 9 mois 4 jours

Protagonist Therapeutics Engages in Key Investment Conferences

Clinical Trials Protagonist Therapeutics Investment Conferences Biopharmaceutical Development Icotrokinra And Rusfertide
BRÈVE

publiée le 26/08/2025 à 22:10, il y a 9 mois 4 jours

Protagonist Therapeutics participe à des conférences d'investissement clés

Essais Cliniques Thérapeutique Protagoniste Conférences D'investissement Développement Biopharmaceutique Icotrokinra Et Rusfertide
COMMUNIQUÉ DE PRESSE

publié le 26/08/2025 à 22:05, il y a 9 mois 4 jours

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Protagonist Therapeutics announced CEO's participation in investment bank conferences in September. Company's advanced Phase 3 clinical development and future plans highlighted

Protagonist Therapeutics Phase 3 Clinical Development NDA Submission Investment Bank Conferences Drug Discovery Programs
BRÈVE

publiée le 25/08/2025 à 13:05, il y a 9 mois 5 jours

Le Rusfertide de Protagonist Therapeutics reçoit la désignation de thérapie révolutionnaire de la FDA

Rusfertide Thérapeutique Protagoniste Polyglobulie Vraie Thérapie Révolutionnaire Phase 3 VÉRIFIER
BRÈVE

publiée le 25/08/2025 à 13:05, il y a 9 mois 5 jours

Protagonist Therapeutics' Rusfertide Receives FDA Breakthrough Therapy Designation

Protagonist Therapeutics Rusfertide Polycythemia Vera Breakthrough Therapy Phase 3 VERIFY
COMMUNIQUÉ DE PRESSE

publié le 25/08/2025 à 13:00, il y a 9 mois 5 jours

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Protagonist Therapeutics' rusfertide granted Breakthrough Therapy Designation by the FDA for polycythemia vera, complementing Orphan Drug and Fast Track designations. NDA filing on track for Q4

FDA Protagonist Therapeutics Rusfertide Breakthrough Therapy Designation NDA Filing

Les Echos

Publié le 29/05/2026 à 22:00, il y a 1 jour

Information on the Annual Financial Statements 2025
Publié le 29/05/2026 à 22:00, il y a 1 jour

Information sur les comptes annuels 2025
Publié le 29/05/2026 à 21:42, il y a 1 jour

Descriptif du programme de rachat d'actions
Publié le 29/05/2026 à 18:00, il y a 1 jour 4 heures

Recticel Group versnelt groei in isolatiepanelen met geïntegreerde isothermische oplossingen na overname Isopanel NV
Publié le 29/05/2026 à 18:00, il y a 1 jour 4 heures

Recticel Group acquires Isopanel NV to deliver integrated solutions in the cold storage panels market

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 30/05/2026 à 04:00, il y a 18 heures 35 minutes

Vanta Announces Strategic Private Placement Financing to Advance U.S. Peptide Market Entry and Integrated Longevity and Consumer Health Sciences Platform
Publié le 30/05/2026 à 02:40, il y a 19 heures 55 minutes

BEACN Announces Financial Results for the First Quarter of 2026 and Update on Loan
Publié le 30/05/2026 à 01:30, il y a 21 heures 5 minutes

Core Critical Approved for Listing on OTCQB(R) Venture Market
Publié le 30/05/2026 à 00:31, il y a 22 heures 4 minutes

Gold Basin Resources Provides Updates on Arrangement with CANEX
Publié le 29/05/2026 à 23:00, il y a 23 heures 35 minutes

The Fresh Factory Reports Q1 2026 Financial Results with 17% Billed Revenue Growth, Completes New Facility Retrofit

Voir tout ACCESSWIRE

EQS Group

Publié le 30/05/2026 à 19:35, il y a 3 heures

THE KILLERS ROCK THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®
Publié le 30/05/2026 à 17:10, il y a 5 heures 25 minutes

MakerWorld's First User-Initiated Charity Contest Names Winners, Bringing Global Creators' Goodwill Directly to Cancer Wards
Publié le 29/05/2026 à 21:42, il y a 1 jour

EQS-Adhoc: Consortium reaches definitive agreement to acquire 4finance Holding’s core consumer lending assets and launch Mellenu Holding
Publié le 29/05/2026 à 21:30, il y a 1 jour 1 heure

Mutares portfolio company F.lli Ferrari Holding has signed an agreement for the partial sale of its Benelux operations to HMF Group
Publié le 29/05/2026 à 20:00, il y a 1 jour 2 heures

Brödernas publishes quarterly report for Jan-Mar 2026